$BIXT
BIOXYTRAN, INC Stock $bixt

$bixt Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010104 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.00K	$573.4K
YoY Change	-98.27%	237.58%
% of Gross Profit
Research & Development	$139.0K	$218.6K	$977.8K
YoY Change	-42.11%	-71.46%	-51.45%
% of Gross Profit
Depreciation & Amortization	$510.00	$910.00	$3.640K
YoY Change
% of Gross Profit
Operating Expenses	$750.2K	$792.9K	$2.134M
YoY Change	-8.41%	-15.28%	-49.36%
Operating Profit	-$750.2K		-$2.134M
YoY Change	-8.41%		-49.36%
Interest Expense	-$67.22K	-$63.81K
YoY Change	-53.41%	2.19%
% of Operating Profit
Other Income/Expense, Net	-$67.74K		-$523.2K
YoY Change	-53.05%		66.83%
Pretax Income	-$818.0K	-$856.7K	-$2.657M
YoY Change	-15.09%	-14.19%	-41.31%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$785.1K	-$805.7K	-$2.464M
YoY Change	-13.94%	-22.4%	-38.89%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.02
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	123.5M shares	123.0M shares	115.1M shares
Diluted Shares Outstanding	123.5M shares		115.1M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.8K	$295.4K	$295.4K
YoY Change	-79.2%	308.24%	308.24%
Cash & Equivalents	$153.8K	$295.4K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$153.8K	$295.4K	$295.4K
YoY Change	-79.2%	308.25%	308.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$79.73K	$75.54K	$75.54K
YoY Change	16.65%	60.95%	60.96%
TOTAL ASSETS
Total Short-Term Assets	$153.8K	$295.4K	$295.4K
Total Long-Term Assets	$79.73K	$75.54K	$75.54K
Total Assets	$233.5K	$370.9K	$370.9K
YoY Change	-71.09%	210.95%	210.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$975.2K	$709.7K	$1.459M
YoY Change	22.44%	33.66%	174.79%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$2.165M	$2.165M	$2.165M
YoY Change	-39.05%	2.02%	2.02%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.294M	$3.663M	$3.663M
YoY Change	-12.14%	11.78%	11.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.294M	$3.663M	$3.663M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.294M	$3.663M	$3.073M
YoY Change	-3.26%	11.78%	6.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.00M	-$11.22M
YoY Change	24.18%	28.15%
Common Stock	$123.5K	$123.3K
YoY Change		11.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.437M	-$2.702M	-$2.702M
YoY Change
Total Liabilities & Shareholders Equity	$233.5K	$370.9K	$370.9K
YoY Change	-71.09%	210.95%	210.96%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$785.1K	-$805.7K	-$2.464M
YoY Change	-13.94%	-22.4%	-38.89%
Depreciation, Depletion And Amortization	$510.00	$910.00	$3.640K
YoY Change
Cash From Operating Activities	-$186.9K	-$156.7K	-$1.806M
YoY Change	-72.97%	9.07%	6.38%
INVESTING ACTIVITIES
Capital Expenditures	$4.710K	$2.100K	$32.25K
YoY Change	-121.1%	-107.51%	-187.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$4.711K	-$2.100K	-$32.25K
YoY Change	-78.89%	-92.49%	-12.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$50.00K	80.00K	$2.061M
YoY Change	-96.38%		16.77%
NET CHANGE
Cash From Operating Activities	-$186.9K	-156.7K	-$1.806M
Cash From Investing Activities	-$4.711K	-2.100K	-$32.25K
Cash From Financing Activities	$50.00K	80.00K	$2.061M
Net Change In Cash	-$141.6K	-78.79K	$223.0K
YoY Change	-121.22%	-54.1%	627.24%
FREE CASH FLOW
Cash From Operating Activities	-$186.9K	-$156.7K	-$1.806M
Capital Expenditures	$4.710K	$2.100K	$32.25K
Free Cash Flow	-$191.6K	-$158.8K	-$1.838M
YoY Change	-71.36%	37.27%	10.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	531000	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001445815
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent		usd
CY2021Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2022	BIXT	Conversion Of Warrants ConversionOfWarrants		usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants		usd
CY2021	BIXT	Non Cash Forfeiture Of Warrants NonCashForfeitureOfWarrants		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	BIXT	Forgiveness Of Related Party Debt Recorded To Additional Paidin Capital ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent		usd
CY2021Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent		usd
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
CY2021	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35027
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIOXYTRAN, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797630
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	75 2nd Ave
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste 605
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Needham
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02494
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	454-1199
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	BIXT
CY2022Q2	dei	Entity Public Float EntityPublicFloat	10379742	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123502235	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2021	dei	Auditor Name AuditorName	Pinnacle Accountancy Group of Utah
CY2021	dei	Auditor Firm AuditorFirmId	6117
CY2021	dei	Auditor Location AuditorLocation	Farmington, Utah
CY2022Q4	us-gaap	Cash Cash	295401	usd
CY2021Q4	us-gaap	Cash Cash	72358	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	295401	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	72358	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	75535	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46932	usd
CY2022Q4	us-gaap	Assets Assets	370936	usd
CY2021Q4	us-gaap	Assets Assets	119290	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	749395	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624316	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	709727	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	531000	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	960	usd
CY2022Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent	38400	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2165000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2122181	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3663482	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3277497	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3663482	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3277497	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123252235	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123252235	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	123252	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	110841	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8392430	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5881876	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-590628	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-397256	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11217600	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8753668	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3158207	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	370936	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119290	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	977768	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2013762	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	933742	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1612685	usd
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	44220	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	5125	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	178382	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	582862	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2134112	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4214434	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2134112	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4214434	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	207117	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	236577	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3644	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312431	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	77031	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-523192	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-313608	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2657304	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4528042	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2657304	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-4528042	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-193372	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-496297	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2463932	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4031745	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115139380	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106252116	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1941256	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	14490	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	14490	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	148070	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	409352	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	121042	usd
CY2021	BIXT	Adjustments To Additional Paid In Capital Forgiveness Of Related Party AdjustmentsToAdditionalPaidInCapitalForgivenessOfRelatedParty	2007187	usd
CY2021	BIXT	Subsidiary Shares Acquired By Affiliate SubsidiarySharesAcquiredByAffiliate	10500	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	450	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	600000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	600000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-496297	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4031745	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3158207	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3158207	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45840	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45840	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	93182	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	93182	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1520371	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	190335	usd
CY2022	BIXT	Adjustments To Additional Paid In Capital Warrant Forfeiture AdjustmentsToAdditionalPaidInCapitalWarrantForfeiture	-6763	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	650000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-193372	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2463932	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2657304	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-4528042	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312431	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	77031	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3644	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	178382	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	582862	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	53371	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-274715	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	125079	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1206088	usd
CY2022	BIXT	Increase Decrease Accounts Payable Related Party IncreaseDecreaseAccountsPayableRelatedParty	178727	usd
CY2021	BIXT	Increase Decrease Accounts Payable Related Party IncreaseDecreaseAccountsPayableRelatedParty	689947	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1805670	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1697399	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	32247	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	36931	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32247	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36931	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	600000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1380960	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1165000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	680000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2060960	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1765000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	223043	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	30670	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72358	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41688	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	295401	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72358	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	104850	usd
CY2022	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants	190335	usd
CY2022	BIXT	Non Cash Forfeiture Of Warrants NonCashForfeitureOfWarrants	-6763	usd
CY2022	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	128859	usd
CY2021	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	119850	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	1400000	usd
CY2022	BIXT	Stock Issued1 One StockIssued1One	1520371	usd
CY2021	BIXT	Stock Issued1 One StockIssued1One	121042	usd
CY2021	BIXT	Forgiveness Of Related Party Debt Recorded To Additional Paidin Capital ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital	2007187	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-193372	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-496297	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zyGATBbSE7y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zKNuitdtU9N7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Debt Conversion Description DebtConversionDescription	The 2021 1-year notes (the “New Notes”), extended thorough May 2023, have an interest rate of 6% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000.
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	6	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.13
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	977768	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2013762	usd
CY2022Q4	us-gaap	Cash Cash	295401	usd
CY2022Q4	BIXT	Working Capital WorkingCapital	-3368080	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11217600	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1467000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	680000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2165000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2020323	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	600000	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	5000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	4500	usd
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	4220	usd
CY2022	BIXT	Reimbursement Of Legal And Administrative Costs ReimbursementOfLegalAndAdministrativeCosts	12000	usd
CY2022	BIXT	Reimbursement Of Rental Cost ReimbursementOfRentalCost	1500	usd
CY2021	BIXT	License Fees Paid LicenseFeesPaid	5125	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	79179	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	46932	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3644	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	75535	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46932	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	709727	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	531000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	709727	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	393085	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	375371	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	134581	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	85685	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	40182	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	32010	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	180557	usd
CY2021Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	131250	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	990	usd
CY2022Q4	BIXT	Unissued Shares Liability Related Party Current UnissuedSharesLiabilityRelatedPartyCurrent	38400	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	960	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2165000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2122181	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3663482	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3277497	usd
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1101846	usd
CY2021Q2	BIXT	Debt Conversion Converted Instrument Accrued Interest Converted DebtConversionConvertedInstrumentAccruedInterestConverted	6060	usd
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	8522125	shares
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2165000	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2165000	usd
CY2022Q4	BIXT	Debt Instrument Interest Payable DebtInstrumentInterestPayable	134581	usd
CY2021Q4	BIXT	Debt Instrument Interest Payable DebtInstrumentInterestPayable	85685	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	42819	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2299581	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2207866	usd
CY2022Q4	BIXT	Debt Instrument Redemption Amount DebtInstrumentRedemptionAmount	2000000	usd
CY2022Q4	BIXT	Debt Instrument Reissue For Settlement Amount DebtInstrumentReissueForSettlementAmount	1000000	usd
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	6081484	shares
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1467000	usd
CY2022Q3	BIXT	Debt Conversion Converted Instrument Accrued Interest Converted DebtConversionConvertedInstrumentAccruedInterestConverted	53371	usd
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	6081484	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123252235	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123252235	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110840998	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110840998	shares
CY2022	BIXT	Stock Issued During Period Issue In Exchange Of Cashless Exercise StockIssuedDuringPeriodIssueInExchangeOfCashlessExercise	4139503	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	272000	shares
CY2020Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.00
CY2021	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	272000	shares
CY2021Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.00
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	492030	shares
CY2022	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.26
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageRemainingContractualTerm2	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	200000	shares
CY2022	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	2.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	22000	shares
CY2022	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 End SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2End	P4Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.48
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	107014	usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P0Y11M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	114519	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	492030	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	492030	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.5552	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.7534	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	524000	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.44
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	524000	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.44
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P0Y11M26D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	114519	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y11M26D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	114519	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7120000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6670000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1500000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1500000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1400000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	7120000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6670000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2870	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	net operating loss carry forwards (NOL), if not utilized, will expire in 2037 for federal purposes
CY2017Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure

Files In Submission

Name	View Source	Status
0001493152-23-010104-index-headers.html	Edgar Link	pending
0001493152-23-010104-index.html	Edgar Link	pending
0001493152-23-010104.txt	Edgar Link	pending
0001493152-23-010104-xbrl.zip	Edgar Link	pending
bixt-20221231.xsd	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
bixt-20221231_def.xml	Edgar Link	unprocessable
bixt-20221231_lab.xml	Edgar Link	unprocessable
bixt-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bixt-20221231_cal.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIXT
BIOXYTRAN, INC Stock $bixt

2023 Q1 Form 10-K Financial Statement

#000149315223010104 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT BIOXYTRAN, INC Stock $bixt

2023 Q1 Form 10-K Financial Statement

#000149315223010104 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT
BIOXYTRAN, INC Stock $bixt